Modality
Gene Therapy
MOA
PRMT5i
Target
JAK1
Pathway
Innate Imm
Bladder Ca
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
Oct 2021
→ Dec 2029
Phase 2Current
NCT06514262
1,203 pts·Bladder Ca
2022-12→2026-02·Completed
NCT03478200
283 pts·Bladder Ca
2021-10→2029-12·Recruiting
1,486 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-271mo agoPh2 Data· Bladder Ca
2029-12-063.7y awayPh2 Data· Bladder Ca
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Recruit…
P2
Complet…
Catalysts
Ph2 Data
2026-02-27 · 1mo ago
Bladder Ca
Ph2 Data
2029-12-06 · 3.7y away
Bladder Ca
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06514262 | Phase 2 | Bladder Ca | Completed | 1203 | MRD |
| NCT03478200 | Phase 2 | Bladder Ca | Recruiting | 283 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |